Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. reported that it issued a press release on December 5, 2025 titled “IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes.” This indicates the company has received a notice of patent allowance in China for technology related to cryogen flow control, which is intended to optimize patient cryoablation outcomes.
The press release, excluding its third paragraph, is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning the disclosure becomes part of those securities offering documents from the date of this report.
IceCure Medical Ltd. (ICCM) submitted a Form 6-K to furnish a press release covering its financial and operational results for the nine months ended September 30, 2025. The press release, dated November 19, 2025 and titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025,” is attached as Exhibit 99.1.
Most of this press release, excluding its third, fourth, and fifth paragraphs, is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8. This means the disclosed information becomes part of those registration statements from the date of this 6-K submission, unless later filings replace it.
IceCure Medical Ltd. reported that it issued a press release announcing that its ProSense® cryoablation system received regulatory approval in Switzerland for use in treating breast, lung, liver, and kidney cancer. The press release, dated November 18, 2025, is furnished as an exhibit to this report. Most of the press release (excluding its second paragraph) is also incorporated by reference into IceCure’s existing shelf and employee equity compensation registration statements on Forms F-3 and S-8, making the Swiss approval disclosure part of those offering documents.
IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.
The submission states this report is incorporated by reference into the company’s existing registration statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical Ltd. (ICCM) announced a management change. On November 5, 2025, the Board promoted Mr. Shay Levav, previously Vice President of Regulatory and Quality Assurance and Clinical Applications since September 2020, to Chief Operating Officer.
The company also furnished a press release on November 10, 2025, and incorporated it by reference into its existing Form F-3 and Form S-8 registration statements.
IceCure Medical (ICCM) furnished a Form 6-K announcing it issued a press release titled “IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival.”
The press release (Exhibit 99.1) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.
The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. reports that the U.S. FDA has granted marketing authorization for its ProSense® cryoablation system to treat low-risk breast cancer in women aged 70 and above. The company furnished two press releases on this authorization, highlighting it as a significant development in providing women with breast cancer a minimally invasive care option. Portions of these press releases are also incorporated by reference into several of IceCure's existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. reports that the U.S. FDA has granted marketing authorization for its ProSense® cryoablation system to treat low-risk breast cancer in women aged 70 and above. The company furnished two press releases on this authorization, highlighting it as a significant development in providing women with breast cancer a minimally invasive care option. Portions of these press releases are also incorporated by reference into several of IceCure's existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. filed a Form 6-K to furnish a press release dated September 30, 2025 about its ProSense® system’s presence at the European Society of Breast Imaging Congress 2025. The release highlights "unlocking de-escalation of care in breast cancer" and positive results from five independent studies. Most of the press release (excluding its second paragraph) is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning that disclosure becomes part of those registration documents going forward unless later superseded.
IceCure Medical Ltd. submitted a Form 6-K reporting that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented.” The press release, excluding its second paragraph, is attached as an exhibit and describes positive clinical results for the company’s ProSense cryoablation technology from four independent studies presented at the CIRSE 2025 annual meeting. The company is also incorporating this press release by reference into several of its existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. submitted a Form 6-K reporting that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented.” The press release, excluding its second paragraph, is attached as an exhibit and describes positive clinical results for the company’s ProSense cryoablation technology from four independent studies presented at the CIRSE 2025 annual meeting. The company is also incorporating this press release by reference into several of its existing Form F-3 and Form S-8 registration statements.